HSPC-sparing treatments for RB-positive abnormal cellular proliferation
This invention is in the area of improved compounds for and methods of treating selected RB-positive cancers and other Rb-positive abnormal cellular proliferative disorders while minimizing the deleterious effects on healthy cells, for example healthy Hematopoietic Stem Cells and Progenitor Cells (HSPCs), associated with current treatment modalities. In one aspect, improved treatment of select RB-positive cancers is disclosed using specific compounds disclosed herein. In certain embodiments, the compounds described herein act as highly selective and, in certain embodiments, short, transiently-acting cyclin-dependent kinase 4/6 (CDK 4/6) inhibitors when administered to subjects.
1. A method for treating retinoblastoma (Rb)-positive non-small cell lung cancer in a human comprising orally administering to the human an effective amount of a selective CDK4/6 inhibitor compound of structure
or a pharmaceutically acceptable salt thereof, wherein the compound is administered to the human at least once a day for 24 or more continuous days.
2. The method of claim 1 , wherein the compound is administered to the human at least once a day for 28 or more continuous days.
3. The method of claim 1 , wherein the compound is administered to the human at least once a day for 35 or more continuous days.
4. The method of claim 1 , wherein the compound is administered to the human twice a day.
5. The method of claim 2 , wherein the compound is administered to the human twice a day.
6. The method of claim 3 , wherein the compound is administered to the human twice a day.
7. The method of claim 1 , further comprising administering to the human at least one additional chemotherapeutic agent.
8. A method for treating progesterone-receptor positive breast cancer in a human comprising orally administering to the human an effective amount of a selective CDK4/6 inhibitor compound of structure
or a pharmaceutically acceptable salt thereof, wherein the compound is administered to the human twice a day for 24 or more continuous days.
9. The method of claim 8 , wherein the compound is administered to the human twice a day for 28 or more continuous days.
10. The method of claim 8 , wherein the compound is administered to the human twice a day for 35 or more continuous days.
11. The method of claim 8 , further comprising administering to the human at least one additional chemotherapeutic agent.
12. The method of claim 11 , wherein the additional chemotherapeutic agent is tamoxifen.
13. The method of claim 11 , wherein the additional chemotherapeutic agent is letrozole.
14. The method of claim 11 , wherein the additional chemotherapeutic agent is anastrozole.
15. The method of claim 11 , wherein the additional chemotherapeutic agent is toremifene.
16. The method of claim 11 , wherein the additional chemotherapeutic agent is goserelin.